At a glance
- Originator GlaxoSmithKline
- Class Antipsychotics
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 05 Nov 1999 New profile
- 05 Nov 1999 Preclinical development for Schizophrenia in United Kingdom (Unknown route)